LithoVue Elite system's real-time IRP monitoring may enhance flexible ureteroscopy for larger stones, offering data-driven pressure management. CVAC 2.0 ureteroscope demonstrates safety and efficacy ...
Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year. In a recent interview with Urology Times®, Kevin C. Zorn, MD, FRCSC, ...
The ProVee Urethral Expander System met safety and effectiveness endpoints in a pivotal phase 3 study, leading to its approval for BPH treatment. Rezūm Water Vapor Therapy received FDA approval for ...
The PROSTOX ultra test predicts late genitourinary toxicity risks in localized prostate cancer patients undergoing stereotactic body radiotherapy. Genomic testing aids in refining treatment intensity ...
The expert faculty discuss the emerging role of circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) as biomarkers in bladder cancer, exploring their prognostic and potentially predictive ...
Flibanserin (Addyi) is now approved for treating HSDD in postmenopausal women, expanding its previous indication for premenopausal women. The FDA's priority review designation for flibanserin ...
Nogapendekin alfa inbakicept combined with BCG shows promise for BCG-unresponsive NMIBC CIS, with a 71% complete response rate in a single-arm trial. The European Medicines Agency's conditional ...
Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...
The Zenflow Spring Implant offers a reversible, durable BPH treatment, preserving natural anatomy with a spring-like implant. The BREEZE study showed a 60% responder rate and 37% IPSS improvement, ...
"The addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival without adversely affecting patient-reported outcomes,” said ...
The ProVee System received FDA approval for treating BPH, offering a safe and effective procedure for symptom relief and quality of life improvement. The ProVIDE study showed significant improvement ...
SYNC-T demonstrated high efficacy in resolving bone metastases in metastatic prostate cancer, achieving an 87% overall response rate in a phase 1 trial. The therapy involves a minimally-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback